Zimmer Biomet Holdings (ZBH) Receiving Somewhat Favorable News Coverage, Accern Reports
Headlines about Zimmer Biomet Holdings (NYSE:ZBH) have trended somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zimmer Biomet Holdings earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 47.0964733905104 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- What’s the Story behind Boston Scientific’s Recent Stock Rally? (marketrealist.com)
- Global spine implant company takes root in new Westminster HQ – Denver Business Journal (bizjournals.com)
- Medical Education Market Is Expected to Reach a Valuation of US$ 38.4 Billion by the End of 2024 (sbwire.com)
- New report: At 6.2+% CAGR restorative dentistry market size is growing strong to 2022 (whatech.com)
- NuVasive Acquires Vetera Spine, Grows With Spinal Hardware (zacks.com)
Shares of Zimmer Biomet Holdings (NYSE:ZBH) opened at 117.09 on Monday. The stock’s 50 day moving average is $114.50 and its 200 day moving average is $120.75. Zimmer Biomet Holdings has a 52 week low of $95.63 and a 52 week high of $133.49. The firm has a market cap of $23.68 billion, a P/E ratio of 33.35 and a beta of 1.21.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Zacks’ consensus estimate of $2.10 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. During the same period in the prior year, the firm earned $2.02 EPS. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. On average, equities research analysts predict that Zimmer Biomet Holdings will post $8.24 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 27.59%.
ZBH has been the topic of a number of recent analyst reports. Royal Bank Of Canada increased their price objective on shares of Zimmer Biomet Holdings from $133.00 to $140.00 and gave the company an “outperform” rating in a research report on Wednesday, June 21st. Bank of America Corporation reaffirmed a “buy” rating and set a $158.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. BidaskClub cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Piper Jaffray Companies reiterated a “buy” rating and set a $135.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Finally, Zacks Investment Research downgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet Holdings presently has an average rating of “Hold” and a consensus price target of $136.55.
In other news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.07% of the company’s stock.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.